Cogan's syndrome: present and future directions

Rheumatol Int. 2009 Aug;29(10):1117-21. doi: 10.1007/s00296-009-0945-0. Epub 2009 May 27.

Abstract

Cogan's syndrome, typified by the combination of interstitial keratitis and immune-mediated sensorineural hearing loss, is a rare condition, and commonly associated with a diagnostic delay. Using a standard search protocol, we review the literature to date, focusing on a number of key areas pertaining to diagnosis, presentation and treatment. Using a case illustration of atypical disease which led to fulminant aortic regurgitation, we highlight the need for continued and collaborative research in order to identify negative prognostic factors and thus tailor therapeutic regimens. Atypical Cogan's syndrome is more commonly associated with systemic manifestations than typical disease, and may be refractory to immunosuppressive treatment. We discuss the application of laboratory (e.g antibodies targeting inner ear antigens) and radiological (PET-CT) aids to disease confirmation and detection of sub-clinical vascular inflammation. As illustrated by the included case description, some patients remain refractory to intense immunosuppression and delineation of adverse prognostic factors which may direct treatment, perhaps including the use of PET-CT, will contribute in the future to improving patient outcomes.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Azathioprine / therapeutic use
  • Dose-Response Relationship, Drug
  • Fatal Outcome
  • Female
  • Hearing Loss, Sensorineural / diagnosis*
  • Hearing Loss, Sensorineural / drug therapy
  • Humans
  • Keratitis / diagnosis*
  • Keratitis / drug therapy
  • Practice Guidelines as Topic
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Syndrome
  • Uveitis / drug therapy
  • Vascular Diseases / diagnosis*
  • Vascular Diseases / drug therapy

Substances

  • Adrenal Cortex Hormones
  • Azathioprine